Immunohistochemical analyses revealed distinct tumor microenvironment features in DPP-4i users, including increased Zeb1+ tumor cells, reduced CD3+ and CD8+ T cell infiltration, and fewer tertiary lymphoid structures (p < 0.001). The gene discussed is CD8A; the disease is neoplasm.